Premium
Updates on bisphosphonates and potential pathobiology of bisphosphonate‐induced jaw osteonecrosis
Author(s) -
Sarin J,
DeRossi SS,
Akintoye SO
Publication year - 2008
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1111/j.1601-0825.2007.01381.x
Subject(s) - osteonecrosis of the jaw , bisphosphonate , zoledronic acid , medicine , pathogenesis , diphosphonates , bisphosphonate associated osteonecrosis of the jaw , bone density conservation agents , complication , dentistry , surgery , pathology , osteoporosis , bone resorption , bone density
Osteonecrosis of the jaws is a major complication associated with long‐term use of bisphosphonates. While osteonecrosis can arise from other precipitating conditions, bisphosphonate‐induced jaw osteonecrosis (BJON) is highly associated with long‐term administration of pamidronate (Aredia ® ) and zoledronic acid (Zometa ® ), which are two intravenous bisphosphonate formulations. The underlying pathogenesis of BJON and its site‐specific presentation still remain to be fully elucidated. This review will discuss clinically available bisphosphonates, current opinions, pathogenesis, and management guidelines for bisphosphonate‐induced jaw osteonecrosis.